We recently reported increased leg lean mass and strength in men with COPD receiving 10 weeks of testosterone (T) and leg resistance training (R). This study evaluates the role of muscle IGF and related factors as potential mechanisms for our findings, using quadriceps muscle biopsies from the same cohort. Patient groups were: 1) weekly placebo (P) injections + no R; 2) P and R; 3) weekly injections of T + no R; and 4) T+R (TR). Muscle fibers were classified histochemically and their cross-sectional areas (CSAs) and fiber density (number of fibers per unit area) determined. Gene transcripts were determined by real-time PCR and protein expression by RIA. While no significant changes in fiber CSAs were noted across groups, increased trends were observed after 10 weeks, and significant decrements in muscle fiber density noted in all treated groups. A global increase in all myosin heavy chain (MyHC) mRNA isoforms was observed in TR patients. Muscle IGF-IEa and IGF-IEc mRNAs were significantly increased with TR group. Muscle IGF-I protein was increased in all intervention groups (greatest in TR). While TR IGF-II mRNA was increased, protein levels were unaltered. IGF binding protein-4 mRNA was increased with TR. Myogenin mRNA was increased in both T groups, while MyoD and myostatin were unchanged. Muscle atrophy F-box mRNA tended to increase with TR. Our data suggest that the combined interventions produced an enhanced local anabolic milieu driven in large part by the muscle IGF system, despite potentially negative biochemical influences present in COPD patients.
INTRODUCTION
In patients with chronic obstructive pulmonary disease (COPD), skeletal muscle dysfunction has recently been highlighted (2) . This is important as it is associated with muscle wasting and weakness and contributes to exercise limitations in these patients (2, 4, 14, 20, 32) . A number of potential mechanisms have been proposed (2) . These include energy imbalance and nutritional depletion (5, 63) , worsened disordered protein turnover with acute exacerbations (72) , deconditioning and impaired energy metabolism (11, 13, 41, 50) , corticosteroids (15) , influences of inflammatory cytokines (16, 18) , hypoxemia, and possible hormonal aberrations impacting on muscle protein turnover. It is thus of interest that reduced serum levels of testosterone and free testosterone have been reported in a substantial proportion of older male patients with COPD (38, 43) .
In a recently published companion paper to the present study (12) , we reported significantly increased leg lean muscle mass and strength following weekly injection of testosterone and resistance training in men with COPD in whom serum testosterone levels were low.
The biochemical mechanisms responsible for improved skeletal muscle bulk and strength with anabolic steroids (i.e., androgens) are not well understood. We (46) and others (71) have reported increased muscle expression of insulin-like growth factor-I (IGF-I) following anabolic steroid administration together with alterations in muscle expression of several IGF binding proteins (BP), which would be expected to facilitate the local effect of IGF-I within the muscle. Thus we believe that the muscle IGF-I system is integral in mediating, at least in part, the growth promoting influences of anabolic steroids. Furthermore, resistance training in both young and older men also results in increased expression of limb muscle IGF-I (54). However, in patients with COPD there are several factors that could potentially lead to dysfunction of the IGF Page 3 of 49 pathways, thus offsetting the positive effects of anabolic steroids and/or resistance training.
These include nutritional depletion, corticosteroids, tumor necrosis factor (TNF)-and other cytokines, all of which are known to depress IGF-I expression (22, 27, 69) .
The aim of this paper was therefore to evaluate the potential role of the muscle IGF-I system and other key biochemical factors influenced by IGF-I (e.g., muscle regulatory factors) in promoting the increased leg lean muscle mass and strength following testosterone administration and resistance training in those COPD patients reported in our companion paper (12) . Vastus lateralis muscle biopsies obtained from the same cohort of COPD patients were analyzed (12) . We hypothesize that despite the potential negative regulatory factors described above, the autocrine/paracrine influence of the muscle IGF system does indeed contribute to the muscle adaptations reported in our recent study (12) . Some of the results of this study have been previously reported in abstract form (26) .
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METHODS
Subjects and Subjects Groups:
Forty patients from our original patient cohort of 47 subjects recently reported in a companion paper (12) , consented to undergo muscle biopsies. These male patients with stable COPD were 55 to 80 years old, had FEV 1 of 60% predicted or less, and FEV 1 to vital capacity ratio of 60% or less. Screening serum testosterone was 400 ng/dl or less (in the lower range for healthy elderly men). Patients with body weight < 75% or > 130% of ideal body weight were excluded.
The study subjects were randomized into 4 groups: a) P: weekly placebo (P; sesame oil) injections intramuscularly; b) T: weekly injections of 100 mg testosterone enanthate (T) in sesame oil intramuscularly; c) PR: weekly P injections and resistance training (R); and d) TR:
weekly T injections and R.
The study duration was 10 weeks. The resistance training sessions were conducted for 45 minutes 3 times per week and included 3 sets per session of each of the following: seated leg press, seated leg curl, seated leg extension, standing calf raise and seated ankle dorsiflexion.
Training intensity was set at 60% of the pre-training one-repetition maximum for the first 4 weeks and increased as tolerated thereafter to 80% of the new one-repetition maximum obtained after 4 weeks of training, for each exercise.
See companion paper and its online supplement for further demographic and methodological details (12) . The study including muscle biopsies was approved by the Institutional Review Boards of the Burns and Allen Research Institute at Cedars-Sinai Medical Center and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and written informed consent was obtained.
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Muscle Sample Preparation:
Percutaneous biopsies of the vastus lateralis were performed at the midportion of the right thigh (15 cm above the patella) under local anesthesia (1% lidocaine) using a needle biopsy technique with applied suction (6) . Muscle samples (an average of roughly 150mg of muscle tissue) were obtained from the same area of the thigh prior to and following the 10-week intervention. The initial biopsies were obtained in testosterone and resistance training-naïve patients. At 10 weeks, the biopsies were obtained between 2 and 5 days following the last training session to avoid acute influences of exercise. Fluid was blotted from a portion of the biopsy, and fat and connective tissue rapidly dissected from the muscle, which was immediately frozen in liquid nitrogen for further mRNA and protein analyses. The remaining muscle specimen was mounted on cork with optimal cutting temperature (O. C. T.) compound (Tissue-Tek, Sakura Finetek U.S.A., Inc., Torrance, CA), oriented for transverse sectioning (i.e., with fibers perpendicular to cork surface) and then rapidly frozen in isopentane, which had been cooled to its melting point by liquid nitrogen. The fresh frozen muscle samples were stored at -80ºC until analysis.
Fiber Type Proportions and Morphometry:
For the assessment of muscle fiber classification and morphometry, serial cross-sections of the muscle sample were cut using a cryostat (Reichert-Jung, model 2800E, Nussloch, Germany) kept at -20ºC. Serial muscle cross-sections of 10 µm thickness were stained for myofibrillar adenosine triphosphatase (mATPase) after alkaline (pH= 9.6), and acid (pH= 4.3 and 4.55) preincubations (10) . One additional serial section was fixed in 2% paraformaldehyde at pH= 7.4 for 2 min at room temperature and then preincubated at pH= 9.6, in a modification of a previously described method (33). These various staining procedures allowed the classification Page 6 of 49 of human muscle fibers into the main 3 fiber types, i.e., types I, IIa, and IIx. In previous studies, the histochemically determined fiber type was also verified immunohistochemically, with 95% or more correspondence between the mATPase-based classification and the major isoform of myosin heavy chain (MyHC) expressed in single muscle fibers (39) . For each muscle sample, fiber type proportions were determined from an analysis of 200-650 fibers within the entire cross-section.
Muscle fiber cross-sectional areas (CSAs) were determined from microscopic images of digitized muscle sections, using a computer-based imaging-processing system. The latter is was used to calibrate the imaging system for morphometry. The CSAs of 100-200 individual fibers (i.e., sampled from those used in the analysis of fiber proportions) were determined from the number of pixels within manually outlined fiber boundaries. Muscle fiber density was determined by measuring the number of fibers per unit area of muscle within the section.
Muscle Protein Analyses:
Protein extraction: Soluble protein was extracted from muscle samples in a 1:10 ratio of cold cell lysis buffer (Cell Signaling Technologies, Beverly, MA) according to manufacturer's protocol. Homogenization was performed with a Polytron homogenizer (Model PT-1200C, KINEMATICA, Inc., Newark, NJ) and homogenates were centrifuged at 14,000 RPM. The supernatant was aliquoted in microcentrifuge tubes. Protein concentration was determined using a commercial protein assay kit (Bio-Rad, Hercules, CA) based on the Bradford (8) method and measured with a spectrophotometer (SmartSpec 3000, Bio-Rad).
IGF-I and IGF-II:
Total muscle IGF-I and IGF-II concentrations were determined using commercial immunoradiometric assays (IRMA) specific for the human peptides and the assays performed according to manufacturer's protocols. Prior to assays, IGF-I and IGF-II were extracted from the sample aliquots and IGFBPs precipitated by incubation with an acid-ethanol solution and the resultant supernatants were neutralized. For IGF-I, a two-site IRMA kit (DSL-5600 ACTIVE ; Diagnostic Systems Laboratories, Webster, TX) was used. The intra-assay coefficient of variation is 1.5% and the inter-assay coefficient of variation is 3.7%. The sensitivity of the assay allows the detection of IGF-I peptide levels of >0.8 ng/ml. For IGF-II, a two-site IRMA kit (DSL-9100 ACTIVE ) was used. The intra-assay coefficient of variation is 4.3% and the inter-assay coefficient of variation is 10.4%. The sensitivity of the assay allows the detection of IGF-II peptide levels of >12 ng/ml.
Muscle mRNA analyses:
Total RNA extraction: Total RNA was extracted from muscle samples with TRIzol reagent (Invitrogen, Carlsbad, CA) according to manufacturer's protocol. Quality and concentrations of total RNA were determined with a spectrophotometer (SmartSpec 3000). Samples were stored at -80°C in RNase-free water until analysis. Two µg total RNA was reverse transcribed (RT) using oligo-dt primers (Invitrogen) and Omniscript RT kit (Qiagen, Valencia, CA) and reactions yielded 20 µl of first-strand cDNA.
Oligonucleotides:
The primers for the genes of interest and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed based on published human cDNA sequences using 
Statistical Analysis
The distribution of data was tested for normality. Statistical analysis was performed using ANOVA (SigmaStat v. 2.0, Jandel, Richmond, CA). If a significant interaction was found, posthoc analysis (Newman-Keuls test) was used to compare differences in independent groups. Intra-group analysis (baseline vs. after intervention) was performed using a paired t test. An level of 0.05 was used to determine significance. Values are presented as means + SEM in all figures and means + SD in Table 2 .
RESULTS
Demographic, Morphometric and Physiologic Data
Demographics and pulmonary function tests are shown in Table 2 . Of note, data for the current 40 patients studied were not significantly different from those reported for the original 47 COPD patients reported in Table 1 of the companion paper (12) . Body composition changes, and in particular leg lean muscle mass changes in the four groups are highlighted in Table 3 and Figure   3 of the companion paper (12) , while changes in quadriceps strength are described in Table 4 and Figure 4 of the paper (12) . In summary, both resistance trained and testosterone groups significantly increased leg lean muscle mass. However, the leg lean muscle mass in the combined testosterone and resistance training group was significantly greater than in resistance training alone. Leg strength significantly improved following both interventions. However, the combination of testosterone and resistance training increased quadriceps strength significantly greater than testosterone alone.
Vastus Lateralis Muscle Fiber Proportions and CSAs
Muscle fiber type proportions for the entire cohort of patients at baseline were: Type I: 41.9 ± and the before versus after changes in muscle fiber CSA per fiber type within specific groups. Despite significant increments in leg lean muscle mass in testosterone treated patients in our companion paper (12) , both sets of analyses yielded non significant differences across all groups for changes in muscle fiber CSA, despite trends (e.g., a mean increase of 19.3% for the CSA of type IIx fibers in TR patients; Figure 2 , upper panel). Despite this, significant decrements in muscle fiber density (i.e., fewer fibers per unit cross-sectional area) were observed after 10 weeks in all three intervention groups (resistance training and/or testosterone) compared to no changes in the P patients (P < 0.05; Figure 2 
, lower panel). See Critical Evaluation of Data in
Discussion section for further analysis.
Biochemical Analyses of the Vastus Lateralis Muscle MyHC mRNA
Analyses of muscle MyHC mRNA abundances across and within groups for fold changes (i.e., values at the end of the intervention versus the baseline) are depicted in Figure 3 . We included the analysis of developmental MyHC isoforms (i.e., embryonic and neonatal) and MyHC Slow/ (usually expressed in the myocardium), as these may be re-expressed with remodeling, injury and repair. Values are expressed as fold change from baseline (horizontal line); thus a value of 1-fold indicates no change following intervention. Across the groups, significant increments in mRNA abundances were observed in the TR patients for MyHC Slow/ (P < 0.05), MyHC 2A (P > 0.05), MyHC 2X (P < 0.05), MyHC Emb (P < 0.001) and MyHC Neo (P < 0.01) compared to P patients. Further, the abundance of MyHC Emb mRNA in TR patients was greater than that observed in the PR group (P < 0.05). For T patients, significant increments were observed for MyHC Slow/ (P = 0.05) compared to P, and for MyHC Emb compared to P (P < 0.001) and PR patients (P < 0.01). There was a trend for increased MyHC Neo in T patients (P = 0.06) compared to P. In PR patients, increased abundance of MyHC 2A was observed compared to P (P < 0.05).
IGF system
Muscle IGF-I mRNA: Analysis across groups revealed a significant relative increment in IGFIEa mRNA (similar to circulating and liver form of IGF-I) abundance in the TR patients compared to P (P < 0.01), PR (P < 0.01), and T (P < 0.05) groups following the 10-week intervention ( Figure 4 ). Of interest, there was a significant positive correlation between the change in muscle mass in TR patients, as reported in our companion paper (12) , and the increased abundance of IGF-IEa mRNA (r = 0.62; P = 0.05). There was also a tendency for the increase in abundance of IGF-IEa mRNA to be greater in the T patients compared to the P group (P = 0.09). The change in abundance of the spliced variant of IGF-I, IGF-IEb (spliced form mostly found in the liver, but present at low levels in muscle), was similar across the groups after 10 weeks (Figure 4) . The abundance of the muscle stretch-sensitive IGF-I spliced variant, IGFIEc (also called mechanogrowth factor, which is induced by stretch, exercise and injury in muscle), was significantly increased in both T and TR groups compared to P (P < 0.001) and PR patients (P < 0.001 and P < 0.01, respectively; Figure 4 ).
Muscle IGF-I protein:
Following the 10-week experimental period, analysis of relative change in IGF-I protein expression across the groups revealed significantly increases for TR patients compared to P (P < 0.01), PR (P < 0.05) and T (P < 0.05) groups ( Figure 5 , left panels). Within each group, significantly increased IGF-I expression (change before versus after) was observed for PR (20%; P < 0.05), T (30%; P < 0.05), and TR (90%; P < 0.001) ( Figure 5 ).
Muscle IGF-II mRNA: Across groups, abundance of IGF-II mRNA was significantly greater for TR patients compared to P (P < 0.01), PR (P < 0.05) and T (P < 0.01) patients following 10 weeks (Figure 4, bottom left panel) .
Muscle IGF-II protein: In contrast, no significant differences in IGF-II muscle protein expression were observed across groups or as a result of the 10 week intervention in any group ( Figure 5, right panels) .
Muscle IGFBP mRNAs: Over the 10-week experimental period, no differences in the changes in IGFBP-3, -5 and -6 mRNA abundances were observed between the groups (Figure 6 ). In contrast, the relative increase in mRNA abundance for IGFBP-4 in the TR group was significantly greater than in all other groups [P (P < 0.05), PR (P < 0.01) and T (P < 0.05)] (Figure 6, upper right panel) . There was a trend for a small decrease in the abundance of IGFBP-4 mRNA in PR compared to P patients (P = 0.07).
Muscle myostatin, MyoD and myogenin mRNAs
Across the groups, no significant changes were observed for either myostatin or MyoD mRNA muscle abundances (i.e., the relative changes in abundance before versus after the experimental period ( Figure 7, left panels) . In contrast, the fold change in myogenin mRNA abundance was significantly greater in T (P < 0.01) and TR (P < 0.001) compared to P patients and there was only a trend for an increase in PR patients (P = 0.06; Figure 7 , upper right panel).
Muscle atrophy F-box (MAFbx)
Despite a mean 1.6 fold increase in MAFbx mRNA abundance in TR patients compared to the other groups, this trend did not achieve statistical significance (P = 0.06 to 0.1; Figure 7 , lower left panel).
DISCUSSION
While both resistance training and testosterone treatment alone exerted positive biochemical and morphometric influences, their combination, like our previous companion paper (12) , had the greatest impact. This includes improved morphometric parameters, increased mRNA abundances of all major MyHC isoforms, enhanced expression of muscle IGF-I and other components of the muscle IGF system, together with increased myogenin expression, a myogenic regulatory factor influenced by IGF-I.
Muscle Morphometry: Critical Evaluation of Data
In the present study, the significant decrease in the number of fibers per unit area of muscle (fiber density) in all intervention groups suggests an increase in muscle mass per unit area. This is consistent with the increment in leg lean muscle mass in all three-intervention groups reported using dual energy X-ray absorptiometry (DEXA), in our companion paper (12) . Similarly, we reported an increase in cumulative muscle fiber area and reduction in relative interstitial space per unit area of diaphragm muscle in hamsters given nandrolone (45). We suggested that the enhanced contractile mass per unit area of the diaphragm in part explained the increased force generating capacity of the diaphragm in nandrolone treated animals (45). Similarly, an increased contractile mass per unit area of the vastus lateralis could contribute to the increased leg strength observed in our patients receiving testosterone and/or resistance training (12) .
However, closer inspection of our data suggests that further mechanistic considerations are necessary, as the reduction in muscle fiber density (similar across all interventions groups) cannot explain the significantly greater increase in leg press strength reported in the patients receiving the combination of testosterone and resistance training (12) . Of interest also, are the wide variances in fiber CSAs and different directions of changes for different fiber types in the TR patients (see Figure 2) . Indeed, the finding that the mean CSA of type I fibers tended to decrease, compared to the 19.3% mean increase in the CSA of type IIx fibers is intriguing. We explored in individual TR patients, the variances in fiber CSA of each fiber type before and after the 10-week intervention. We found significantly greater variances in fiber size for each type following the intervention (e.g., 2 to 3 fold increment) in each TR patient compared to baseline values (Fournier, preliminary data). We postulate that these interesting findings may be the result of 2 possible mechanisms.
The first mechanism is that muscle fiber hypertrophy induced by the interventions may stress the metabolic and diffusion reserves as well as the critical myonuclear domain size of very large fibers, resulting in splitting. This has been well described in rats and cats following weight lifting exercise (31,37) and in stretch-enlarged avian muscle (3). Morphologically, the longitudinal split muscle fibers were observed as a "pinching off" of a segment from the parent fiber (37) . In patients with neuromuscular disorders, longitudinal splitting of mainly type I fibers was reported in muscle biopsies exhibiting significant fiber hypertrophy (64) . We believe that muscle fiber splitting is a positive adaptive response to maintain optimal homeostasis in muscle tissue. A second possible mechanism is that of de novo muscle fiber formation. With this in mind, an increase in muscle satellite cell number and enhanced expression of androgen receptors on satellite cells have been reported with testosterone treatment in male subjects and human satellite cell cultures, respectively (65, 66) . Further, increased satellite cell activation and presence of small fibers were demonstrated in forearm muscles of cats following weight lifting exercises due to presumed de novo fiber formation (28) . In preliminary studies (Fournier, unpublished observations) we have observed significant increments in the number of myonuclei per muscle fiber with TR. Thus either or both mechanisms could contribute to enhanced variances in fiber size in response to testosterone and/or resistance training. In addition, other influences may contribute to variances in fiber size observed in this study. These include regional variations in fiber size within the muscle depending on site and depth, age, pre-existing co-morbidities and levels of exercise, etc. (19,21,47,48,56,59 ).
Muscle Fiber Proportions and MyHC mRNA Abundances
In the present study, histochemical procedures for ATPase were employed to classify muscle fibers into the major types. It is now well described that hybrid fibers co-expressing different MyHCs are present, although generally accounting for small percentages of the total proportions in aggregate. This type of analysis cannot be performed from an ATPase-based approach.
Changes in MyHC mRNAs most attributed to T include MyHC Slow/ and MyHC Emb isoforms, while most attributed to resistance training include the fast isoforms (MyHC 2A and MyHC 2X ).
The predominant changes in the abundances of MyHC mRNA isoforms however, occurred in the TR patients. Of interest, there appears to be a global increase in expression of the various major isoforms (Slow/ , 2A, 2X) in these patients. It is unclear whether protein expression after the 10-week intervention would track the mRNA abundances. If this were the case, a global increase in MyHCs might in part explain the preserved fiber type proportions in the TR patients.
Testosterone treatment was associated with an increase in abundance of developmental MyHCs.
Of interest, immunohistochemically, MyHC Emb appeared to be expressed only in very small fibers, while MyHC Neo was expressed in larger fibers of varying sizes and types (Fournier, unpublished observations). We postulate that the expression of MyHC Emb in very small fibers reflects the presence of new fiber formation as a component of the remodeling process as described above.
Muscle Biochemistry
Some provocative biochemical data were evident following the various treatments. Although gene expression studies were conducted at only one time point after 10 weeks of treatment, it should be emphasized however, that treatments were continued throughout the study and so the data obtained with the final biopsy reflect ongoing stimuli over 10 weeks and should not be judged as one might the impact of an initial stimulus studied 10 weeks later. We interpret mRNA changes therefore to reflect both recent and ongoing influences of the interventions.
Nevertheless, early changes in signaling pathways may have been missed. This is however, an unavoidable limitation in human studies, which constrains the number of invasively derived samples as in our study.
In the ensuing discussion, we will compare and contrast our data with those in the literature and where possible, distinguish anabolic steroid effects from those of resistance training. Studies evaluating acute responses over hours to several days were not included as these responses are not relevant to the long-term interventions we employed.
IGF-IEa mRNA, IGF-I Protein and Anabolic Steroids:
In recent years, there has been increasing appreciation that the hypertrophic response of muscle fibers to anabolic steroids is due at least in part to the anabolic effects of IGF-I acting locally in an autocrine/paracrine fashion.
We previously reported this in the diaphragm of rats receiving nandrolone (46). Further, altered expression of muscle IGFBPs was noted and interpreted as facilitating local muscle IGF-I action.
It should be noted that most assays of IGF-I mRNA in muscle previously reported in the literature, likely reflect the IGF-IEa isoform. In elderly men given testosterone, similar increments in IGF-I mRNA abundance were reported in the vastus lateralis muscle (71) . More recently, the increment in muscle IGF-I mRNA abundance in elderly men was reported to be greater with the combination of testosterone and growth hormone (GH) than GH alone (9).
Further, testosterone administration produced sustained increments in IGF-I muscle protein expression over a 6-month period while the expression of androgen receptors in muscle increased for only the first 4 weeks (23). It should be emphasized however, that healthy elderly men represent a distinct separate patient population from elderly men with COPD in whom skeletal muscle dysfunction has been highlighted (2). Nevertheless we postulated that testosterone would still have the potential to significantly impact on the local IGF system (perhaps in an attenuated fashion) despite the potential negative regulatory factors present in our patients with COPD. The significant increase in the abundance of IGF-IEa in the TR patients, is thus in line with this hypothesis. Further, the change in the abundance of IGF-IEa mRNA correlated positively with the change in lean muscle mass in TR patients reported in our companion paper (12) . These changes occurred despite reports of enhanced expression of inflammatory cytokines in COPD subjects, compared to controls (16, 18, 73) , where cytokines such as TNF-may suppress IGF-I expression (22) .
IGF-IEa mRNA, IGF-I Protein and Resistance Training:
There is a paucity of data on local muscle IGF-I responses to resistance training and no data in the COPD population. Sixteen weeks of resistance training in the young and older men revealed a 2-fold increase in vastus lateralis muscle IGF-IEa mRNA for both groups, compared to baseline (54). Similar results were reported in another studies following 12 weeks of resistance training in healthy elderly males (34) and after 8 weeks of strength training in young men (42) . Increased immunohistochemical staining for IGF-I was reported in vastus lateralis biopsies from elderly subjects after 10 weeks of strength training (24) . Thus resistance training might be expected to promote a local anabolic milieu. It is therefore not unexpected that in our study, the combination of testosterone and resistance training had enhanced effects. Further, both resistance training itself and IGF-I may enhance expression of key myogenic regulatory factors (25, 52, 57) .
Our results thus demonstrate a distinct impact of both resistance training and testosterone on IGF-1 muscle expression with a positive interactive influence of the combined interventions.
IGF-IEb:
IGF-IEb is a spliced variant of IGF-I, which has greater abundance in the liver than in extra-hepatic tissues (67) . While expressed in skeletal muscle, its precise function is unknown.
There are no reports of the effect of anabolic steroids on muscle IGF-IEb mRNA abundance. 
IGF-II:
There are no reports of the effect of anabolic steroids on muscle IGF-II expression. In elderly men subjected to resistance training, vastus lateralis biopsies at 14 and 24 weeks failed to show enhanced IGF-II mRNA expression (68) . IGF-II has an important role in myoblast differentiation, prevention of apoptotic cell death, and repair following injury (67). As postulated above, extreme hypertrophy of muscle fibers, which outstrip their nuclear domain size and diffusion reserves, could lead to de novo fiber synthesis and/or fiber splitting. Further, resistance training could result in muscle fiber injury (58) . In the present study, the increased abundance of IGF-II and myogenin (a myogenic regulatory factor) in the TR patients might thus reflect muscle reparative processes, remodeling and stimuli for new fiber formation (25, 49) . The Myogenin, MyoD, and MRF4 mRNA abundances however, have been reported to be significantly elevated following acute resistance exercise in male subjects (57) and following 16 weeks of resistance training in young and older adults with lower expression in the elderly (40) .
In the latter study, protein levels were not significantly increased (40) . In contrast, muscle myogenin protein increased following 10 weeks of resistance training in young subjects (36).
In the present study, the increased expression of myogenin mRNA in T and TR patients and a trend for increase in the PR group supports further enhancement of an anabolic stimulus within the muscle by both interventions. Our findings may be explained by the influences of increased IGF-I expression. Further, both IGF-I and myogenin have been reported to be up regulated in skeletal muscle with injury and regeneration (51) and would clearly be important factors in the repair processes and the differentiation of newly formed myoblasts, as postulated above (25) .
MyoD is an important factor in the transcriptional control of myogenesis. Its expression is not temporally linked to myogenin and thus non-parallel changes in their expression are not surprising, especially at a single 10-week time point. Further, protein expression of the regulatory factors was not determined. We thus cannot exclude important contributions from MyoD.
Myostatin: Myostatin, a skeletal muscle growth inhibitor is a member of the transforming growth factor superfamily. Enhanced expression is associated with muscle wasting. In the present study, muscle myostatin mRNA abundance was not significantly affected in any of the intervention groups, though modest trends for reduction were seen in all three. A significant reduction in myostatin gene expression has been reported in human subjects following strength training in one study (60) , but not in another (42) . We cannot exclude however decreased myostatin protein expression after our 10-week intervention.
MAFbx: MAFbx, also known as Atrogin-1, is a muscle specific E3 ligase and an important mediator of the ubiquitin-proteasome system, the major pathway through which muscle protein degradation occurs (7, 30 ). An increase in both MAFbx and MuRF1 mRNA was recently reported following 8 weeks of resistance training (44). While the apparent increase in MAFbx in the TR patients appears at face value counter-intuitive (as this is the group that experienced the greatest increased in muscle mass), other feasible postulates for this direction of change can be made. In keeping with our postulate of muscle remodeling including muscle fiber splitting, injury and repair, up-regulation of MAFbx may well be necessary to clear myofibrillar debris and optimize the local milieu for myogenesis. Indeed myofibrillar disassembly is a necessary step prior to activation of the ubiquitin-proteasome system (17) .
Limitations of Current Study
While this study provides an abundance of new and intriguing data that should prompt multiple future lines of investigation, several limitations should be highlighted. While we considered adding two control populations, i.e., normal healthy age-matched subjects and age-matched COPD patients but with normal serum testosterone levels, this was not undertaken for several reasons. Firstly, it is well established that distinct differences in both limb and respiratory muscles exist in COPD patients compared to controls. Thus, the response to testosterone and to resistance training is likely very different. Furthermore, in the present study, each COPD patient acted as their own controls, providing more relevant data for this patient population. Logistical issues as well as excessive costs and time commitment also precluded adding two extra groups to the existing four groups studied. Indeed, the present study, funded by two major grants, took several years to complete. In addition it was unclear whether this would provide cost-effective additional clarifications such restoration of muscle function and/or biochemical markers by the interventions. While comparisons from the literature were cited regarding the impact of anabolic steroids or resistance training on limb muscle, in our discussion, the relevance of these comparisons remain very limited. These studies were mainly performed in normal subjects and thus exhibit no disease specificity. In addition, studies are often in young individuals in whom adaptations differ from those in the elderly (e.g., 54).
Morphometric and biochemical analyses on human muscle tissue are limited by great variances between subjects. Thus the total number of subjects per group that were studied was relatively low and likely accounted for several trends that were observed in this study.
Both mRNA and protein analyses were performed. The amount of tissue required for protein analysis (e.g., immunoblot, RIA) limited the number of assays that could be performed. While the use of mRNA analysis may be limited by the fact that changes in abundance may well have occurred earlier than after 10 weeks, some intriguing data were nevertheless found and are of interest (i.e., transient changes in muscle gene expression may have bee missed). This was limited by the fact that we did not consider a greater number of biopsies justified, as this intervention was invasive and provided no direct benefits to the patients. We thus elected to limit our analysis to those adaptations present at the conclusion of the study.
In summary, the increased leg muscle mass and strength in male COPD patients with low serum testosterone levels, who received testosterone, resistance training or the combination (12) , was associated with increased cumulative fiber CSA per unit area of muscle, as suggested by decreased fiber density. This should result in increased contractile muscle protein per unit area.
Further, the combined interventions produced a distinctly enhanced local anabolic milieu driven in large part by the muscle IGF system, despite potentially negative biochemical influences present in patients with COPD. While our data provide strong inferences for the morphometric and biochemical mechanisms underlying improved lean leg structure and function, as reported in our companion paper, they do not provide conclusive cause and effect relationships. Lastly, our data also provide strong inferences that fiber remodeling and/or new fiber formation was induced, as adaptations to the combined interventions challenge fiber diffusion reserve and/or critical myonuclear domain size associated with rapidly induced changes in fiber morphometry. Upper panel: CSAs of all fiber types were unchanged after 10 weeks in P subjects. In other groups, changes in individual fiber CSA (types I, IIa, IIx) did not achieve statistical significance.
Nevertheless, incremental trends in CSAs were observed. For example, PR increased by 10.0 -11.7% and T increased by 6.8 -7.1%. In TR subjects type IIa CSAs increased by 7.2% while a 19.3% increase was noted in type IIx fibers. In type I fibers a 7.6% reduction in CSA was observed.
Lower panel: In P patients, no changes were observed in fiber density after 10 weeks. Significant decreases in fiber density (i.e., fewer fibers per unit area) were observed for intervention groups (PR, 12.8%; T, 12.7%; and TR, 11.9%). * Significantly different from P. Values are means ± SE for both panels. Table 2 . Demographics and pulmonary function results at study entry (Mean ± SD).
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